Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Profit after tax (before exceptional items) up 23% to Rs 215 crores
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The company's Bavla site was successfully jointly inspected by the EDQM and Italian Medicines Agency (AIFA)
InvaGen has received 5 inspectional observations in Form 483
The inspection was a cGMP Inspection and had ended with NIL observations
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Subscribe To Our Newsletter & Stay Updated